Earlier this week, Teva Pharmaceutical Industries Ltd. (Teva) announced that the UK Medicines & Healthcare Regulatory Agency (MHRA) approved ONGAVIA, a ranibizumab biosimilar.
An international coalition of aviation and medical professionals from countries like the United States, United Kingdom, France, and Switzerland have published a statement raising serious concerns about the compromise in aviation safety due to COVID-19 vaccine injuries among the flight crew.
MHRA today granted a licence for Ongavia (ranibizumab), a biosimilar to Lucentis , for the treatment of (wet) age-related macular degeneration (AMD) and several other eye diseases, such as diabetic
A major UK trial to examine whether different coronavirus vaccines can safely be used for two-dose regimens has now been expanded to include the Moderna and Novavax vaccines, with results expected to be reported in a matter of months.